Interferon and Interferon-Inducible Gene Activation in Patients with Type 1 Diabetes

Scandinavian Journal of Immunology

Volumn 80, Issue 4, 2014, Pages 283-292

  Panarina, M ^a   Kisand, K ^a   Alnek, K ^a   Heilman, K ^a,b   Peet, A ^a,b   Uibo, R ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b TARTU UNIVERSITY HOSPITAL   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; HELICASE; INTERFERON; ALPHA INTERFERON; ANTIGEN; CCL5 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; CXCL9 CHEMOKINE; CXCL9 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; DEAD BOX PROTEIN; IFI44 PROTEIN, HUMAN; IFIH1 PROTEIN, HUMAN; MESSENGER RNA; MHC CLASS II TRANSACTIVATOR PROTEIN; MX2 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; NUCLEAR PROTEIN; RANTES; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON INDUCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UPREGULATION; BIOSYNTHESIS; BLOOD; ENTEROVIRUS; ENTEROVIRUS INFECTION; GENETICS; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHILD; CHILD, PRESCHOOL; CYTOSKELETAL PROTEINS; DEAD-BOX RNA HELICASES; DIABETES MELLITUS, TYPE 1; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; FEMALE; GENE EXPRESSION; HUMANS; INFANT; INTERFERON-ALPHA; MALE; MYXOVIRUS RESISTANCE PROTEINS; NUCLEAR PROTEINS; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; UP-REGULATION; YOUNG ADULT;

EID: 84926462050     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12204     Document Type: Article

References (61)

1. Lind K, Hühn MH, Flodström-Tullberg M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clin Exp Immunol 2012;168:30-8.
2. Coppieters KT, Wiberg A, Tracy SM, von Herrath MG. Immunology in the clinic review series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma. Clin Exp Immunol 2012;168:5-11.
3. Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007690.
4. Ylipaasto P, Klingel K, Lindberg AM et al. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 2004;47:225-39.
5. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 2009;52:1143-51.
6. Stene LC, Rewers M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies. Clin Exp Immunol 2012;168:12-23.
7. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 2011;342:d35.
8. Serreze DV, Wasserfall C, Ottendorfer EW et al. Diabetes acceleration or prevention by a coxsackievirus B4 infection: critical requirements for both interleukin-4 and gamma interferon. J Virol 2005;79:1045-52.
9. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009;324:387-9.
10. Smyth DJ, Cooper JD, Bailey R et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006;38:617-9.
11. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20.
12. Melén K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem 1996;271:23478-86.
13. de Veer MJ, Holko M, Frevel M et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001;69:912-20.
14. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8 + effector T cells. J Leukoc Biol 2002;71:669-76.
15. Wen X, Kudo T, Payne L, Wang X, Rodgers L, Suzuki Y. Predominant interferon-γ-mediated expression of CXCL9, CXCL10, and CCL5 proteins in the brain during chronic infection with Toxoplasma gondii in BALB/c mice resistant to development of toxoplasmic encephalitis. J Interferon Cytokine Res 2010;30:653-60.
16. Butticè G, Miller J, Wang L, Smith BD. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res 2006;98:472-9.
17. Fujioka T, Honda M, Yoshizaki T et al. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C. Intern Med 2010;49:1987-90.
18. Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract 2009;86:e19-21.
19. Nakamura K, Kawasaki E, Abiru N et al. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review. Endocr J 2010;57:947-51.
20. Ogihara T, Katagiri H, Yamada T et al. Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C. Intern Med 2009;48:1387-90.
21. Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med 2010;49:403-7.
22. Hober D, Chehadeh W, Weill J et al. Circulating and cell-bound antibodies increase coxsackievirus B4-induced production of IFN-alpha by peripheral blood mononuclear cells from patients with type 1 diabetes. J Gen Virol 2002;83:2169-76.
23. Wong FS, Wen L. IFN-alpha can both protect against and promote the development of type 1 diabetes. Ann N Y Acad Sci 2008;1150:187-9.
24. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-51.
25. Davis AM, Ramos HJ, Davis LS, Farrar JD. Cutting edge: a T-bet-independent role for IFN-alpha/beta in regulating IL-2 secretion in human CD4 + central memory T cells. J Immunol 2008;181:8204-8.
26. Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, Farrar JD. Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8 + effector versus central memory T-cell fates. Blood 2009;113:5516-25.
27. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003;19:225-34.
28. Le Bon A, Thompson C, Kamphuis E et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006;176:2074-8.
29. Axtell RC, Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012;248:23-35.
30. Corre B, Perrier J, El Khouri M, Cerboni S, Pellegrini S, Michel F. Type I interferon potentiates T-cell receptor mediated induction of IL-10-producing CD4(+) T cells. Eur J Immunol 2013;43:2730-40.
31. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000;342:301-7.
32. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 1999;44:21-6.
33. Hekkala A, Ilonen J, Knip M, Veijola R, Register FPD. Family history of diabetes and distribution of class II HLA genotypes in children with newly diagnosed type 1 diabetes: effect on diabetic ketoacidosis. Eur J Endocrinol 2011;165:813-7.
34. Viskari H, Ludvigsson J, Uibo R et al. Relationship between the incidence of type 1 diabetes and enterovirus infections in different European populations: results from the EPIVIR project. J Med Virol 2004;72:610-7.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
36. Kisand K, Link M, Wolff AS et al. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008;112:2657-66.
37. Oikarinen M, Tauriainen S, Oikarinen S et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 2012;61:687-91.
38. Schulte BM, Bakkers J, Lanke KH et al. Detection of enterovirus RNA in peripheral blood mononuclear cells of type 1 diabetic patients beyond the stage of acute infection. Viral Immunol 2010;23:99-104.
39. Nairn C, Galbraith DN, Taylor KW, Clements GB. Enterovirus variants in the serum of children at the onset of Type 1 diabetes mellitus. Diabet Med 1999;16:509-13.
40. Salminen K, Sadeharju K, Lönnrot M et al. Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J Med Virol 2003;69:91-8.
41. Huang X, Yuang J, Goddard A et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995;44:658-64.
42. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993;260:1942-6.
43. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003;100:2610-5.
44. Petri M, Wallace DJ, Spindler A et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21.
45. Rice GI, Forte GM, Szynkiewicz M et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol 2013;12:1159-69.
46. Irvine KM, Gallego P, An X et al. Peripheral blood monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes. Diabetes 2012;61:1281-90.
47. Levy H, Wang X, Kaldunski M et al. Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes. Genes Immun 2012;13:593-604.
48. Kang DC, Gopalkrishnan RV, Lin L et al. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 2004;23:1789-800.
49. Allen JS, Pang K, Skowera A et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 2009;58:138-45.
50. von Herrath M. Diabetes: A virus-gene collaboration. Nature 2009;459:518-9.
51. Chistiakov DA, Voronova NV, Savost'Anov KV, Turakulov RI. Loss-of-function mutations E6 27X and I923V of IFIH1 are associated with lower poly(I:C)-induced interferon-β production in peripheral blood mononuclear cells of type 1 diabetes patients. Hum Immunol 2010;71:1128-34.
52. Stene LC, Oikarinen S, Hyöty H et al. Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 2010;59:3174-80.
53. Winkler C, Lauber C, Adler K et al. An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes 2011;60:685-90.
54. Downes K, Pekalski M, Angus KL et al. Reduced expression of IFIH1 is protective for type 1 diabetes. PLoS ONE 2010;5:e12646.
55. Yang H, Wang Z, Xu K et al. IFIH1 gene polymorphisms in type 1 diabetes: genetic association analysis and genotype-phenotype correlation in Chinese Han population. Autoimmunity 2012;45:226-32.
56. Aminkeng F, Van Autreve JE, Weets I et al. IFIH1 gene polymorphisms in type 1 diabetes: genetic association analysis and genotype-phenotype correlation in the Belgian population. Hum Immunol 2009;70:706-10.
57. Jermendy A, Szatmári I, Laine AP et al. The interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes in both the high-incidence Finnish and the medium-incidence Hungarian populations. Diabetologia 2010;53:98-102.
58. Bouças AP, Brondani LA, Souza BM et al. The A allele of the rs1990760 polymorphism in the IFIH1 gene is associated with protection for arterial hypertension in type 1 diabetic patients and with expression of this gene in human mononuclear cells. PLoS ONE 2013;8:e83451.
59. Liu S, Wang H, Jin Y et al. IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet 2009;18:358-65.
60. Zouk H, Marchand L, Polychronakos C. Study of transcriptional effects in Cis at the IFIH1 locus. PLoS ONE 2010;5:e11564.
61. Chehadeh W, Weill J, Vantyghem MC et al. Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J Infect Dis 2000;181:1929-39.